Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for XRF Scientific's Debt-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, XRF Scientific's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XRF Scientific Debt-to-Asset vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, XRF Scientific's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where XRF Scientific's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XRF Scientific (ASX:XRF) has a Debt-to-Asset of 0.03 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on XRF Scientific and its competitors.
Is XRF Scientific's Debt-to-Asset too high?
XRF Scientific's current Debt-to-Asset is 0.03. Overall, XRF Scientific has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XRF Scientific's Debt-to-Asset compare to MMM and HON?
XRF Scientific's Debt-to-Asset of 0.03 can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Conglomerates company?
A good Debt-to-Asset depends on the Conglomerates industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on XRF Scientific and its competitors. XRF Scientific's current Debt-to-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XRF Scientific stock overvalued right now?
Based on GuruFocus' analysis, XRF Scientific (ASX:XRF) is currently considered Modestly Overvalued. The stock's GF Value™ is A$1.67, compared to a current price of A$1.86 — trading 11.4% above its estimated fair value. The current Debt-to-Asset is 0.03. XRF Scientific's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For XRF Scientific (ASX:XRF), the current Debt-to-Asset is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XRF Scientific (ASX:XRF) Overvalued in 2026?
Based on GuruFocus' analysis, XRF Scientific stock appears to be overvalued.
The current stock price of A$1.86 is trading 11.4% above its estimated GF Value™ of A$1.67.
GuruFocus considers XRF Scientific to be Modestly Overvalued.
Key valuation signals for ASX:XRF:
Debt-to-Asset: 0.03
GF Value™: A$1.67 vs. price of A$1.86 (11.4% above fair value)
No single metric tells the full story. See the ASX:XRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XRF Scientific Ltd is engaged in the business of manufacturing and marketing precious metal products, specialized chemicals and instruments for the scientific, analytical and mining industries. It operates through the following segments: Capital Equipment, Precious Metals, and Consumables. The company generates maximum revenue from the Capital Equipment segment that Manufactures sample preparation products and analytical instruments. Geographically, it derives a majority of revenue from Australia and also has a presence in Canada and Europe. Some of its product includes Electric Fusion Machines; Fusion Flux; Crushing and Pulverising, platinum lab ware and others.
94GF Score
Get the complete analysis for ASX:XRF
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:XRF has been successfully added to your 
